Hongene Biotech Corporation

We are thrilled to introduce??????????????——Novel cap analog designs developed by Hongene for enhanced mRNA immune evasion??! Rapid advancements in the mRNA therapeutics field underscore the potential of this groundbreaking technology to address medical needs across multiple disease areas and the critical role of ongoing innovation. At the cutting edge of mRNA innovation, we strive to enhance the efficacy, safety, and overall impact of mRNA-based treatments. Our goal is to deliver unparalleled value to patients and our collaborators, pushing the boundaries of what's possible in therapeutic development. The chemistry of the 5' mRNA end cap is crucial for stability and translation of mRNA drug modalities. Designed to enhance translation efficiency during immune stress, our HiXCap? novel cap structures offer a promising solution for improving mRNA-based therapeutics. Studies carried out in????? ?????????? and????? ???????? inflammation models have demonstrated their potential to transform treatment outcomes. As we look to the future, we are confident that studies in NHPs and human clinical trials will reveal even more pronounced advantages of HiXCap? structures, ultimately enhancing treatment outcomes across a wide range of disease indications! Download our latest brochure to explore more about our innovative solution??. Connect with our experts today???https://lnkd.in/ejdFEmsE. #mRNA #RNAtherapeutics #mRNAcapping #mRNACDMO

It has been a fantastic week at #DCATWeek 2025, marked by insightful presentations, meaningful conversations, and new partnerships! A big Thank You to everyone who connected with us ?? ! Our Hongene team is grateful for the opportunity to share our expertise in oligonucleotides and mRNA raw materials and CDMO services. The event may be over, but our journey continues. We look forward to working with you in achieving even more remarkable results in your Oligonucleotides and mRNA Therapeutics projects! Feel free to reach out to us anytime: https://lnkd.in/ejdFEmsE! #Biopharmaceutical #oligonucleotides #mRNAvaccine #RNAtherapeutics #drugdevelopment

#Breakingnews Alnylam Pharmaceuticals announces the FDA approval of AMVUTTRA? (vutrisiran), the first RNAi therapeutic designed to reduce cardiovascular death, hospitalizations, and urgent heart failure visits in adults with ATTR amyloidosis with cardiomyopathy (ATTR-CM). ATTR-CM is a devastating, rapidly progressive, and ultimately fatal disease. There is no cure for ATTR-CM, and the deposition of misfolded transthyretin (TTR) fibrils causes irreversible damage over time which can lead to premature death. AMVUTTRA is an innovative RNAi therapeutic that works by rapidly knocking down the production of transthyretin (TTR), the protein responsible for causing ATTR amyloidosis. This novel mechanism of action addresses the disease at its source, providing a targeted and effective treatment option. Administered via subcutaneous injection just four times a year, AMVUTTRA offers a convenient and efficient solution for patients. The approval of AMVUTTRA is based on the results of the HELIOS-B Phase 3 clinical trial, which demonstrated significant improvements in cardiovascular outcomes, functional capacity, and quality of life for patients. The trial achieved statistical significance on all 10 pre-specified primary and secondary endpoints, with a 28% reduction in the risk of all-cause mortality and recurrent cardiovascular events during the double-blind treatment period. These results were published in The New England Journal of Medicine, further validating the clinical value of AMVUTTRA. The FDA approval of AMVUTTRA for ATTR-CM offers a new and clinically differentiated treatment option and represents a significant step forward in the fight against ATTR amyloidosis. By addressing both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis, AMVUTTRA provides comprehensive care for patients, improving their quality of life and potentially extending their lifespan. Congratulations to Alnylam Pharmaceuticals??! Find out more: https://lnkd.in/d8Z888jC #RNAtherapeutics #RNAi #siRNA #GeneSilencing #RNA #geneticdiseases

Get off to a good start at DCAT (Drug, Chemical & Associated Technologies Association) Week 2025 ?? ! At #DCATWeek, we had the privilege of connecting with colleagues and engaging with so many insightful presentations. We are also grateful for the opportunity to share our expertise in oligonucleotides and mRNA raw materials and CDMO services! Tomorrow marks the final day of this incredible event! If you are there, come by and say hi, we look forward to seeing you for more exciting conversations! Judy Zhu Yihang Chen John ZHAN #Biopharmaceutical #oligonucleotides #mRNAvaccine #RNAtherapeutics #drugdevelopment

A comprehensive overview of the current landscape of Oligonucleotide therapeutics (ONTs) in clinical trials! ONTs have emerged as a rapidly evolving modality for cancer treatment, leveraging their ability to modulate gene expression with high specificity. Over 20 nucleic acid-based therapies have received regulatory approval, and advancements in chemical modifications, sequence optimization, and novel delivery systems have transformed ONTs from research tools to clinically viable agents. This review highlights the clinical applications of ONTs, focusing on their role in cancer therapy, particularly in immunotherapy, and the challenges in their clinical translation. 1?? ???????? ???? ?????????????? ???????????????? ??????????????: The review discusses various ONT strategies targeting cancer cells directly, such as ASOs, siRNAs, and decoy molecules. Specific examples include AZD4785 targeting KRAS, trabedersen targeting TGF-b2, and imetelstat targeting telomerase. These strategies aim to down regulate oncogenes or activate tumor suppressors. 2?? ???????? ?????? ???????????? ??????????????????????????: The review explores the use of ONTs to enhance cancer immunotherapy by targeting immune checkpoint proteins, modulating immune cell function, and overcoming tumor immune evasion. Strategies include CpG oligonucleotides, TLR9 agonists, and STAT3 inhibitors. Clinical trials involving these approaches are discussed, highlighting their potential to augment antitumor immune responses. 3?? ???????????????? ?????????????????????????????? ????????????????????: The review highlights innovative approaches such as RNA editing, saRNAs, and aptamers. These strategies aim to modulate gene expression at the transcriptional or post-transcriptional level, offering new avenues for cancer treatment. 4?? ???????????????? ????????????????????: The review emphasizes the importance of effective delivery systems for ONTs, including LNPs, exosomes, and tissue-specific conjugates. These delivery systems aim to improve the stability, targeting, and cellular uptake of ONTs, addressing challenges related to off-target effects and tissue penetration. This review stands out for its comprehensive clinical focus, detailed analysis of delivery systems, integration of immunotherapy, and forward-looking perspective on emerging therapeutic approaches, making it a valuable resource for researchers and clinicians in the clinical application of ONTs in cancer therapy! Find out more: https://lnkd.in/eT4cabQ7 Congratulations to all contributors??! Vittorio de Franciscis Giovanni Amabile Marcin Kortylewski #Oligonucleotidetherapeutics #RNAtherapeutics #ASO #siRNA #cancertherapy #immunotherapy #clinicalresearch

A recent study presents a novel therapeutic approach for prion disease by utilizing Zinc Finger Repressors (ZFRs) delivered via AAV to significantly reduce prion protein (PrP) expression! Prion disease is a devastating neurodegenerative disorder caused by the misfolding of the PrP into toxic species, leading to neurodegeneration and death. Despite extensive research, there is currently no approved treatment for prion disease, underscoring the urgent need for effective therapeutic strategies. Scientists from Sangamo Therapeutics, Inc. and Broad Institute of MIT and Harvard explore a novel epigenetic regulation approach using ZFRs to specifically reduce PrP expression at the transcriptional level, aiming to provide a potential treatment for prion disease and other neurological disorders. They evaluated the efficacy of ZFRs delivered via AAV in reducing prion mRNA expression and extending survival in prion disease mice. In vitro experiments demonstrated that ZFRs could potently and specifically reduce prion mRNA expression by >95%. In vivo studies in wildtype mice showed that ZFRs stably lowered neuronal PrP expression throughout the central nervous system for at least 17 months. The study also tested the impact of ZFRs on survival in mice inoculated with misfolded PrP, demonstrating significant lifespan extension and reduced PrP levels in the brain. Additionally, the study delivered a ZFR targeting the human prion gene (PRNP) to cynomolgus monkeys using a novel blood-brain-barrier penetrant AAV capsid, achieving widespread PRNP repression across the brain. The findings not only demonstrate the potential of ZFRs as a one-time intravenous treatment for prion disease but also highlight their broader applicability for treating other neurological disorders, offering a promising avenue for future research and clinical development. Congratulations to all contributors??! Shih-Wei Chou Amy Pooler Sonia Vallabh Eric Vallabh Minikel Bryan Zeitler Find out more about the manuscript: https://lnkd.in/eh6C93SR #PrionDisease #GeneTherapy #genomicmedicine #neurology

Our Hongene team had a great time at the 2025 OPT Congress in Boston! We had the privilege of engaging with leaders and pioneers in the field, discussing the latest advances in next-generation therapeutics. It was a valuable experience, and we’re grateful for the connections we made. The congress may be over, but our journey continues. Let's keep in touch and explore more exciting collaborations together! Feel free to reach out to our experts John ZHAN Judy Zhu anytime, or leave us a message here: https://lnkd.in/ejdFEmsE! #OPTCongress #mRNA #Oglionucleotides #RNAtherapeutics

Recent research presents a novel approach to enhancing the sensitivity and efficiency of RNA detection using fluorogenic probes in quantitative polymerase chain reaction (qPCR)! qPCR is a widely used method for the simultaneous amplification and quantitative detection of gene transcripts and genomes. Traditional qPCR methods rely on fluorescent dyes or probes to track DNA amplification in real time. The performance of fluorogenic probes is heavily dependent on the design, particularly the choice of fluorophore and quencher moieties, and the linkers used to attach them to oligonucleotides. Led by researchers from McGill University, this study aims to improve the sensitivity and efficiency of qPCR by optimizing the design of fluorogenic probes, focusing on the linker chemistry and internal placement of quenchers. The researchers designed and synthesized a series of fluorogenic probes with different linker chemistries and quencher placements. They introduced a novel three-way branched glycerol ‘X’ linker that allows for modular incorporation of various quenchers in a sequence-independent manner. This design avoids sequence constraints imposed by nucleobase conjugates and enhances flexibility and compatibility with diverse quenchers. The probes were synthesized using solid-phase synthesis techniques and purified by anion exchange HPLC. The performance of the probes was evaluated using RT-qPCR assays targeting the RNA genomes of SARS-CoV-2, influenza A, and influenza B viruses. The study compared the sensitivity, efficiency, and signal-to-noise ratio of the probes with different linker designs. The study demonstrated that the glycerol ‘X’ linker significantly improved the performance of fluorogenic probes in RT-qPCR assays. The probes with the ‘X’ linker exhibited superior sensitivity, with single-molecule detection limits approaching four copies of RNA. The glycerol ‘X’ linker offers a practical and scalable solution for developing sensitive, efficient, and robust diagnostic assays, particularly valuable in pandemic situations where rapid and accurate testing is crucial. Future studies could explore the adaptation of this linker design to other probe types and diagnostic platforms. Congratulations to all contributors??！Bruktawit M. Maureen McKeague Nathan Luedtke Masad J. Damha, PhD, FCIC Find out more: https://lnkd.in/eeeKqBJi #qPCR #oligonucleotides #moleculardiagnostics #nucleicacids

We are thrilled to announce our membership with DCAT (Drug, Chemical & Associated Technologies Association). ? As the premier event for the?global pharmaceutical manufacturing value chain, #DACTWeek is an incredible opportunity to connect with industry leaders to strengthen partnerships and foster strategic collaborations! ? Meet our team, ?????????? ????, VP of US market, ?????? ????????, GM of Oligo Business, and BD manager John ZHAN Judy Zhu Yihang Chen, to explore more about our extensive experience and capabilities in oligonucleotides and mRNA raw materials and CDMO services! ? #Biopharmaceutical #oligonucleotides #RNAtherapeutics #CDMO #mRNA

??What a great day at RNA Leaders Europe 2025! Our Vice President of EU Market Dr. Michael Leuck and Dr. Lisa Bornewasser, our mRNA Technical Sales Specialist, had a great time connecting with friends in the?RNA space! If you're in Basel, please visit us at Booth #10. Our team is more willing to discuss with you and explore how we can support your projects with our extensive experience in nucleic acid raw materials and CDMO services! #RNAtheraputics #RNAMedicines #RNAleaders #ASO #siRNA #mRNA #oligonucleotides #CDMO